Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Lung09: BL-B01D1 + Osimertinib in Resectable EGFR-mutated NSCLC
NCT07642024Phase 3Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Major Pathological Response at 24 months. Started Jul 2026; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07642024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07642024.